Détail - canceropole-wordpress

Impact of Positive Resection Margins on Recurrence and Survival Following Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG PA-6 Randomized Controlled Trial.

Lambert A, Salleron J, Harlé A, Biagi JJ, Leroux A, Thomas J, Monard L, Cros J, Marchal F, Ayav A, Conroy T

Ann Surg. 2024 07 23;:

Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO.

Blay JY, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, Saada-Bouzid E, Firmin N, Bertucci F, Marec-Berard P, Ray-Coquard I, Lervat C, Rolland F, Thyss A, Conroy T, Brahmi M, Dufresne A, Merrouche Y, Brunat-Mentigny M, Biron P, Bompas E, Perol D,

Eur J Cancer. 2024 07 15;208:114228

Role of molecular biology in the management of pancreatic cancer.

Boileve A, Smolenschi C, Lambert A, Boige V, Tarabay A, Valery M, Fuerea A, Pudlarz T, Conroy T, Hollebecque A, Ducreux M

World J Gastrointest Oncol. 2024 07 15;16(7):2902-2914

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.

Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Boilève A, Delaye M, Gourgou S, Pezzella V, Borg C

Ann Oncol. 2024 07 8;:

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.

Fraunhoffer N, Hammel P, Conroy T, Nicolle R, Bachet JB, Harlé A, Rebours V, Turpin A, Abdelghani MB, Mitry E, Biagi J, Chanez B, Bigonnet M, Lopez A, Evesque L, Lecomte T, Assenat E, Bouché O, Renouf D, Lambert A, Monard L, Mauduit M, Cros J, Iovanna J, Dusetti N

Ann Oncol. 2024 06 19;:

Is neoadjuvant folfox an effective treatment only in a very selected favorable subgroup of locally advanced rectal cancer?

Riou O, Castan F, Conroy T

Cancer Radiother. 2024 06 12;:

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study.

Zhou K, Robert M, Seegers V, Blanc-Lapierre A, Savouroux S, Bigot F, Frenel JS, Campone M, Conroy T, Penault-Llorca F, Raoul JL, Bellanger MM

PLoS One. 2024 05 31;19(5):e0304556

Acceptability and usefulness of the EORTC 'Write In three Symptoms/Problems' (WISP): a brief open-ended instrument for symptom assessment in cancer patients.

Rojas-Concha L, Arrarrás JI, Conroy T, Chalk T, Guberti M, Holzner B, Husson O, Kuliś D, Shamieh O, Piccinin C, Puga MJ, Rohde G, Groenvold M,

Health Qual Life Outcomes. 2024 03 26;22(1):28

The role of total neoadjuvant therapy in locally advanced rectal cancer: a survey of specialists attending the All-Ireland Colorectal Cancer Conference 2022 including lead investigators of OPRA, PRODIGE-23 and RAPIDO.

O'Brien T, Hospers G, Conroy T, Lenz HJ, Smith JJ, Andrews E, O'Neill B, Leonard G

Ir J Med Sci. 2023 12 23;:

Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.

Neuzillet C, Bouché O, Tournigand C, Chibaudel B, Bauguion L, Bengrine-Lefevre L, Lopez-Trabada Ataz D, Mabro M, Metges JP, Péré-Vergé D, Conroy T, Lièvre A, Andre M, Desseigne F, Goldwasser F, Henriques J, Anota A, Hammel P

J Natl Compr Canc Netw. 2023 12;21(12):1234-1242.e17

Development and psychometric evaluation of item banks for memory and attention - supplements to the EORTC CAT Core instrument.

Rogge AA, Petersen MA, Aaronson NK, Conroy T, Dirven L, Fischer F, Habets E, Reijneveld JC, Rose M, Sleurs C, Taphoorn M, Tomaszewski KA, Vachon H, Young T, Groenvold M,

Health Qual Life Outcomes. 2023 11 15;21(1):124

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.

Nicolle R, Bachet JB, Harlé A, Iovanna J, Hammel P, Rebours V, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lopez A, Biagi J, François E, Artru P, Lambert A, Renouf DJ, Monard L, Mauduit M, Dusetti N, Conroy T, Cros J

J Clin Oncol. 2023 11 14;:JCO2202668

Moving toward Precision Oncology Centers V2.0.

Dogan S, Cournède PH, Solary E, Heard JM, Aldea M, Conroy T, Robert C, André F

Ann Oncol. 2023 10 5;:

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19).

Seegers V, Rousseau G, Zhou K, Blanc-Lapierre A, Bigot F, Mahammedi H, Lambert A, Moreau-Bachelard C, Campone M, Conroy T, Penault-Llorca F, Bellanger MM, Raoul JL

Cancers (Basel). 2023 09 28;15(19):

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O'Reilly EM, Hackert T, Golan T, Prager G, Haustermans K, Vogel A, Ducreux M,

Ann Oncol. 2023 09 5;:

Validation and optimization of the French Generic Adherence for Chronic Diseases Profile (GACID-P) using classical test and item response theory.

Rotonda C, Guillemin F, Conroy T, Alleyrat C, Lefevre B, Soudant M, Tarquinio C

Health Qual Life Outcomes. 2023 05 24;21(1):49

Adjuvant and neoadjuvant approaches in pancreatic cancer.

Conroy T, Lambert A, Ducreux M

Curr Opin Oncol. 2023 05 15;:

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis.

Bascoul-Mollevi C, Gourgou S, Borg C, Etienne PL, Rio E, Rullier E, Juzyna B, Castan F, Conroy T

Eur J Cancer. 2023 03 24;186:151-165

When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials.

Touraine C, Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C

BMC Med Res Methodol. 2023 02 10;23(1):36

[Examining the use of palliative systemic treatments near end-of-life for patients with metastatic cancer at a French cancer institute].

Minot L, Conroy T, Salleron J, Henry A

Bull Cancer. 2022 11 30;:

COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19).

Seegers V, Rousseau G, Zhou K, Blanc-Lapierre A, Bigot F, Mahammedi H, Lambert A, Moreau-Bachelard C, Campone M, Conroy T, Penault-Llorca F, Boisdron-Celle M, Bellanger M, Raoul JL

Cancers (Basel). 2022 11 11;14(22):

Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data.

Yeh C, Zhou M, Sigel K, Jameson G, White R, Safyan R, Saenger Y, Hecht E, Chabot J, Schreibman S, Juzyna B, Ychou M, Conroy T, Fojo T, Manji GA, Von Hoff D, Bates SE

Oncologist. 2022 11 11;:

Development of a Clinical-Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial.

Egea J, Salleron J, Gourgou S, Ayav A, Laurent V, Juzyna B, Harlé A, Conroy T, Lambert A

Cancers (Basel). 2022 10 16;14(20):

Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial.

Winter A, Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C

Qual Life Res. 2022 09 17;:

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.

Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P,

JAMA Oncol. 2022 09 1;:

Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial.

Legrand T, Salleron J, Conroy T, Marchal F, Thomas J, Monard L, Biagi JJ, Lambert A

Cancers (Basel). 2022 08 16;14(16):

Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments.

Haidari RE, Anota A, Dabakuyo-Yonli TS, Guillemin F, Conroy T, Velten M, Jolly D, Causeret S, Cuisenier J, Graesslin O, Abbas LA, Nerich V

Qual Life Res. 2022 05 19;:

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.

Pijnappel EN, Suurmeijer JA, Koerkamp BG, Kos M, Siveke JT, Salvia R, Ghaneh P, van Eijck CHJ, van Etten-Jamaludin FS, Abrams R, Brasiuniene B, Büchler MW, Casadei R, van Laethem JL, Berlin J, Boku N, Conroy T, Golcher H, Sinn M, Neoptolemos JP, van Tienhoven G, Besselink MG, Wilmink JW, van Laarhoven HWM

JAMA Oncol. 2022 Apr 21;:

COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19).

Zhou K, Raoul JL, Blanc-Lapierre A, Seegers V, Boisdron-Celle M, Bourdon M, Mahammedi H, Lambert A, Moreau-Bachelard C, Campone M, Conroy T, Penault-Llorca F, Bellanger MM, Bigot F

Clin Med Insights Oncol. 2022 ;16:11795549221090187

Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials.

Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C

Qual Life Res. 2021 Nov 24;:

Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study.

Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J

Clin Colorectal Cancer. 2021 Oct 3;:

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer.

Lambert A, Schwarz L, Ducreux M, Conroy T

Cancers (Basel). 2021 Sep 21;13(18):

Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients-First Results from the PAPESCO-19 Cohort Study.

Zhou K, Blanc-Lapierre A, Seegers V, Boisdron-Celle M, Bigot F, Bourdon M, Mahammedi H, Lambert A, Campone M, Conroy T, Penault-Llorca F, Bellanger MM, Raoul JL

Cancers (Basel). 2021 Jul 6;13(14):

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.

Blay JY, Boucher S, Le Vu B, Cropet C, Chabaud S, Perol D, Barranger E, Campone M, Conroy T, Coutant C, De Crevoisier R, Debreuve-Theresette A, Delord JP, Fumoleau P, Gentil J, Gomez F, Guerin O, Jaffré A, Lartigau E, Lemoine C, Mahe MA, Mahon FX, Mathieu-Daude H, Merrouche Y, Penault-Llorca F, Pivot X, Soria JC, Thomas G, Vera P, Vermeulin T, Viens P, Ychou M, Beaupere S

ESMO Open. 2021 Apr 17;6(3):100134

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C,

Lancet Oncol. 2021 Apr 13;:

Future directions in drug development in pancreatic cancer.

Lambert A, Conroy T, Ducreux M

Semin Oncol. 2021 Feb 23;:

Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans.

Sigel K, Zhou M, Park YA, Mutetwa T, Nadkarni G, Yeh C, Polak P, Sigel C, Conroy T, Juzyna B, Ychou M, Fojo T, Wisnivesky JP, Bates SE

Semin Oncol. 2021 Feb 23;:

Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17.

Cuer B, Mollevi C, Anota A, Charton E, Juzyna B, Conroy T, Touraine C

BMC Med Res Methodol. 2020 Sep 3;20(1):223

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.

Bascoul-Mollevi C, Barbieri A, Bourgier C, Conroy T, Chauffert B, Hebbar M, Jacot W, Juzyna B, De Forges H, Gourgou S, Bonnetain F, Touraine C, Anota A

Qual Life Res. 2020 Aug 18;:

Metastatic Pancreatic Cancer: ASCO Guideline Update.

Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D

J. Clin. Oncol.. 2020 Aug 5;:JCO2001364

Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented.

Farge D, Bournet B, Conroy T, Vicaut E, Rak J, Zogoulous G, Barkun J, Ouaissi M, Buscail L, Frere C

Cancers (Basel). 2020 Mar 6;12(3):

[Recourse of patients to their general practitioner in unplanned hospitalization in oncology management: A prospective study in an oncology institute].

Tomasso D, Salleron J, Lamouille C, Baumard F, Conroy T, Henry A

Bull Cancer. 2020 Feb 5;:

An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45.

Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, Conroy T, Inwald EC, Serpentini S, Pinto M, Weis J, Morag O, Lindviksmoen Astrup G, Tomaszweksi KA, Pogoda K, Sinai P, Sprangers M, Aaronson N, Velikova G, Greimel E, Arraras J, Bottomley A,

Ann. Oncol.. 2020 Feb;31(2):283-288

International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer.

Petersen MA, Aaronson NK, Conroy T, Costantini A, Giesinger JM, Hammerlid E, Holzner B, Johnson CD, Kieffer JM, van Leeuwen M, Nolte S, Ramage JK, Tomaszewski KA, Waldmann A, Young T, Zotti P, Groenvold M,

Qual Life Res. 2020 Jan 18;:

Definitive Chemoradiotherapy for Esophageal Squamous Cell Cancer: A Matter of Standard.

Adenis A, Crehange G, Conroy T

J. Clin. Oncol.. 2019 Jul 29;:JCO1900963

Factors of the evolution of fatigue dimensions in patients with breast cancer during the 2 years after surgery.

Person H, Guillemin F, Conroy T, Velten M, Rotonda C

Int. J. Cancer. 2019 Jun 22;:

Sensitivity to change of the EORTC quality of life module measuring cancer related fatigue (EORTC QlQ-Fa12): results from the international psychometric validation.

Weis J, Wirtz MA, Tomaszewski KA, Hammerlid E, Arraras JI, Conroy T, Lanceley A, Schmidt H, Singer S, Pinto M, Alm El-Din M, Compter I, Holzner B, Hofmeister D, Chie WC, Harle A, Flechtner HH, Bottomley A,

Psychooncology. 2019 Jun 21;:

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T

Clin Colorectal Cancer. 2019 May 3;:

Adjuvant treatment of pancreatic cancer.

Conroy T, Ducreux M

Curr Opin Oncol. 2019 Apr 15;:

Combination or single-agent chemotherapy as adjuvant treatment for pancreatic cancer?

Conroy T, Van Laethem JL

Lancet Oncol.. 2019 Mar;20(3):336-337

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).

Adenis A, Bennouna J, Etienne PL, Bogart E, Francois E, Galais MP, Ben Abdelghani M, Michel P, Metges JP, Dahan L, Conroy T, Ghiringhelli F, Drouillard A, El Hajbi F, Samalin E, Hiret S, Delaine-Clisant S, Mariette C, Penel N, Piessen G, Le Deley MC

Eur. J. Cancer. 2019 Feb 21;111:12-20

An update on treatment options for pancreatic adenocarcinoma.

Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducreux M, Conroy T

Ther Adv Med Oncol. 2019 ;11:1758835919875568

Systemic treatment of pancreatic cancer revisited.

Ducreux M, Seufferlein T, Van Laethem JL, Laurent-Puig P, Smolenschi C, Malka D, Boige V, Hollebecque A, Conroy T

Semin. Oncol.. 2018 Dec 27;:

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB,

N. Engl. J. Med.. 2018 Dec 20;379(25):2395-2406

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C

JAMA Oncol. 2018 Oct 25;:

An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45.

Bjelic-Radisic V, Bottomley A, Cardoso F, Cameron D, Brain E, Kuljanic K, de Costa RA, Conroy T, Inwald E, Serpentini S, Pinto M, Weis J, Morag O, Guro Lindviksmoen Astrup G, Tomaszweksi K, Pogoda K, Sinai P, Sprangers MAG, Aaronson N, Greimel E

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii59-viii60

Chemotherapy for pancreatic cancer: the rise of multidrug regimens.

Malka D, Borbath I, Conroy T

Lancet Gastroenterol Hepatol. 2018 Oct;3(10):659-660

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).

Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P, ,,,,,,,,,

Dig Liver Dis. 2018 Aug 18;:

The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.

Petersen MA, Aaronson NK, Arraras JI, Chie WC, Conroy T, Costantini A, Dirven L, Fayers P, Gamper EM, Giesinger JM, Habets EJJ, Hammerlid E, Helbostad J, Hjermstad MJ, Holzner B, Johnson C, Kemmler G, King MT, Kaasa S, Loge JH, Reijneveld JC, Singer S, Taphoorn MJB, Thamsborg LH, Tomaszewski KA, Velikova G, Verdonck-de Leeuw IM, Young T, Groenvold M,

Eur. J. Cancer. 2018 Jun 21;100:8-16

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM

Lancet Oncol.. 2018 Mar;19(3):e151-e160

The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer.

Manneville F, Rotonda C, Conroy T, Bonnetain F, Guillemin F, Omorou AY

Cancer. 2018 Feb 15;124(4):797-806

Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?

Adenis A, Castan F, Conroy T

Radiother Oncol. 2018 Jan 10;:

Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7).

Brédart A, Anota A, Young T, Tomaszewski KA, Arraras JI, Moura De Albuquerque Melo H, Schmidt H, Friend E, Bergenmar M, Costantini A, Vassiliou V, Hureaux J, Marchal F, Tomaszewska IM, Chie WC, Ramage J, Beaudeau A, Conroy T, Bleiker E, Kulis D, Bonnetain F, Aaronson NK,

Eur J Cancer Care (Engl). 2018 Jan;27(1):

Towards a standardised definition for fundamental care: A modified Delphi study.

Feo R, Conroy T, Jangland E, Muntlin Athlin Å, Brovall M, Parr J, Blomberg K, Kitson A

J Clin Nurs. 2017 Dec 26;:

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.

Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah J, Mahé M, Bécouarn Y, Dupuis O, Lledo G, Seitz J, Bedenne L, Gourgou-Bourgade S, Juzyna B, Conroy T, Gérard J

Ann. Oncol.. 2017 Oct;28(10):2436-2442

Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).

Robert M, Jarlier M, Gourgou S, Desseigne F, Ychou M, Bouché O, Juzyna B, Conroy T, Bennouna J

Oncology. 2017 Oct;93(6):

Development of an item bank for computerized adaptive testing of self-reported cognitive difficulty in cancer patients.

Dirven L, Taphoorn MJ, Groenvold M, Habets EJ, Aaronson NK, Conroy T, Reijneveld JC, Young T, Petersen MA,

Neurooncol Pract. 2017 Sep;4(3):189-196

Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials.

Barbieri A, Peyhardi J, Conroy T, Gourgou S, Lavergne C, Mollevi C

BMC Med Res Methodol. 2017 Sep;17(1):148

Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.

Lambert A, Gavoille C, Conroy T

Therap Adv Gastroenterol. 2017 Aug;10(8):631-645

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.

Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T

Eur. J. Cancer. 2017 Aug;84:239-249

Psychometric evaluation of an item bank for computerized adaptive testing of the EORTC QLQ-C30 cognitive functioning dimension in cancer patients.

Dirven L, Groenvold M, Taphoorn MJB, Conroy T, Tomaszewski KA, Young T, Petersen MA,

Qual Life Res. 2017 Jul;:

International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12).

Weis J, Tomaszewski KA, Hammerlid E, Ignacio Arraras J, Conroy T, Lanceley A, Schmidt H, Wirtz M, Singer S, Pinto M, Alm El-Din M, Compter I, Holzner B, Hofmeister D, Chie WC, Czeladzki M, Harle A, Jones L, Ritter S, Flechtner HH, Bottomley A,

J. Natl. Cancer Inst.. 2017 May;109(5):

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Gérard JP, André T, Bibeau F, Conroy T, Legoux JL, Portier G, Bosset JF, Cadiot G, Bouché O, Bedenne L,

Dig Liver Dis. 2017 Apr;49(4):359-367

The European organization for research and treatment of cancer - satisfaction with cancer care questionnaire: revision and extended application development.

Brédart A, Beaudeau A, Young T, Moura De Alberquerque Melo H, Arraras JI, Friend L, Schmidt H, Tomaszewski KA, Bergenmar M, Anota A, Costantini A, Marchal F, Tomaszewska IM, Vassiliou V, Chie WC, Hureaux J, Conroy T, Ramage J, Bonnetain F, Kulis D, Aaronson NK,

Psychooncology. 2017 Mar;26(3):400-404

Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.

Ducreux M, Bennouna J, Adenis A, Conroy T, Lièvre A, Portales F, Jeanes J, Li L, Romano A

Cancer Chemother. Pharmacol.. 2017 Jan;79(1):9-16

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.

Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T

PLoS ONE. 2017 ;12(9):e0183288

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.

Péron J, Roy P, Conroy T, Desseigne F, Ychou M, Gourgou-Bourgade S, Stanbury T, Roche L, Ozenne B, Buyse M

Oncotarget. 2016 Dec;7(50):82953-82960

Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time.

Ousmen A, Conroy T, Guillemin F, Velten M, Jolly D, Mercier M, Causeret S, Cuisenier J, Graesslin O, Hamidou Z, Bonnetain F, Anota A

Health Qual Life Outcomes. 2016 Dec;14(1):167

Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial.

Barbieri A, Anota A, Conroy T, Gourgou-Bourgade S, Juzyna B, Bonnetain F, Lavergne C, Bascoul-Mollevi C

Med Decis Making. 2016 Jul;36(5):615-28

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Groot Koerkamp B

Lancet Oncol.. 2016 Jun;17(6):801-10

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

Créhange G, Conroy T

J Thorac Dis. 2016 Jun;8(6):1014-8

Current standards and new innovative approaches for treatment of pancreatic cancer.

Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M

Eur. J. Cancer. 2016 Apr;57:10-22

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D,

Ann. Oncol.. 2015 Sep;26 Suppl 5:v56-68

Development of an item bank for computerized adaptive test (CAT) measurement of pain.

Petersen MA, Aaronson NK, Chie WC, Conroy T, Costantini A, Hammerlid E, Hjermstad MJ, Kaasa S, Loge JH, Velikova G, Young T, Groenvold M

Qual Life Res. 2015 Aug 13.

Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.

Vincent J, Mariette C, Pezet D, Huet E, Bonnetain F, Bouche O, Conroy T, Roullet B, Seitz JF, Herr JP, Di Fiore F, Jouve JL, Bedenne L

Eur J Cancer. 2015 Jul 7. pii: S0959-8049(15)00495-5

Chemotherapy at the End of Life: Factors of Prescription.

Massard V, Salleron J, Krakowski I, Conroy T, Weber B

J Palliat Med. 2015 Jun 18.

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

Levy A, Azria D, Pignon JP, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Leclercq J, Juzyna B, Ezra P, Lemanski C, Deutsch E

Radiother Oncol. 2015 Mar;114(3):415-6

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pelissier S, Collette L

Eur J Cancer. 2014 Nov;50(17):2983-93

Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.

Ducreux M, Giovannini M, Baey C, Llacer C, Bennouna J, Adenis A, Peiffert D, Mornex F, Abbas M, Boige V, Pignon JP, Conroy T, Cellier P, Juzyna B, Viret F

Dig Liver Dis. 2014 Oct;46(10):950-5

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A

Lancet Oncol. 2014 Mar;15(3):305-14

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.

Samalin E, Bouche O, Thezenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissiere F, Laurent-Puig P, Ychou M, Mazard T

Br J Cancer. 2014 Mar 4;110(5):1148-54

Impact of response shift on time to deterioration in quality of life scores in breast cancer patients.

Hamidou Z, Dabakuyo-Yonli TS, Guillemin F, Conroy T, Velten M, Jolly D, Causeret S, Graesslin O, Gauthier M, Mercier M, Bonnetain F

PLoS One. 2014 May 14;9(5):e96848

Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality of life study in breast cancer patients.

Anota A, Bascoul-Mollevi C, Conroy T, Guillemin F, Velten M, Jolly D, Mercier M, Causeret S, Cuisenier J, Graesslin O, Hamidou Z, Bonnetain F

Health Qual Life Outcomes. 2014 Mar 8;12:32

Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.

Francois E, Azria D, Gourgou-Bourgade S, Jarlier M, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Seitz JF, Conroy T, Juzyna B, Gerard JP

Radiother Oncol. 2014 Jan;110(1):144-9

Psychometric evaluation of the EORTC computerized adaptive test (CAT) fatigue item pool.

Petersen MA, Giesinger JM, Holzner B, Arraras JI, Conroy T, Gamper EM, King MT, Verdonck-de Leeuw IM, Young T, Groenvold M

Qual Life Res. 2013 Nov;22(9):2443-54

Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.

Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Paris E, Juzyna B, Ezra P, Azria D

Ann Oncol. 2013 Nov;24(11):2834-8

Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13).

Weis J, Arraras JI, Conroy T, Efficace F, Fleissner C, Gorog A, Hammerlid E, Holzner B, Jones L, Lanceley A, Singer S, Wirtz M, Flechtner H, Bottomley A

Psychooncology. 2013 May;22(5):1002-7

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu

Ducreux M, Adenis A, Pignon JP, Francois E, Chauffert B, Ichante JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T

Eur J Cancer. 2013 Apr;49(6):1236-45

The role of the FOLFIRINOX regimen for advanced pancreatic cancer.

Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M

Curr Oncol Rep. 2013 Apr;15(2):182-9

The EORTC computer-adaptive tests measuring physical functioning and fatigue exhibited high levels of measurement precision and efficiency.

Petersen MA, Aaronson NK, Arraras JI, Chie WC, Conroy T, Costantini A, Giesinger JM, Holzner B, King MT, Singer S, Velikova G, Verdonck-de Leeuw IM, Young T, Groenvold M

J Clin Epidemiol. 2013 Mar;66(3):330-9

Response shift effects on measuring post-operative quality of life among breast cancer patients: a multicenter cohort study.

Dabakuyo TS, Guillemin F, Conroy T, Velten M, Jolly D, Mercier M, Causeret S, Cuisenier J, Graesslin O, Gauthier M, Bonnetain F

Qual Life Res. 2013 Feb;22(1):1-11

Factors associated with fatigue after surgery in women with early-stage invasive breast cancer.

Rotonda C, Guillemin F, Bonnetain F, Velten M, Conroy T

Oncologist. 2013;18(4):467-75

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Boige V, Berille J, Conroy T

J Clin Oncol. 2013 Jan 1;31(1):23-9

Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2.

Rullier A, Gourgou-Bourgade S, Jarlier M, Bibeau F, Chassagne-Clement C, Hennequin C, Tisseau L, Leroux A, Ettore F, Peoc'h M, Diebold MA, Robin YM, Kleinclaus I, Mineur L, Petitjean C, Mosnier JF, Soubeyran I, Padilla N, Lemaistre AI, Berille J, Denis B, Conroy T, Gerard JP

Eur J Cancer. 2013 Jan;49(1):82-9

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La Roche G, Bouche O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahe MA, Becouarn Y, Dupuis O, Lledo G, Seitz JF, Bedenne L, Juzyna B, Conroy T

J Clin Oncol. 2012 Dec 20;30(36):4558-65

Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.

Le Tourneau C, Kamal M, Tredan O, Delord JP, Campone M, Goncalves A, Isambert N, Conroy T, Gentien D, Vincent-Salomon A, Pouliquen AL, Servant N, Stern MH, Le Corroller AG, Armanet S, Rio Frio T, Paoletti X

Target Oncol. 2012 Dec;7(4):253-65

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?

Bonnetain F, Bosset JF, Gerard JP, Calais G, Conroy T, Mineur L, Bouche O, Maingon P, Chapet O, Radosevic-Jelic L, Methy N, Collette L

Eur J Cancer. 2012 Aug;48(12):1781-90

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi JM, Seitz JF, Adenis A, Hennequin C, Denis B, Ducreux M

J. Clin. Oncol.. 2012 Jun;30(16):1941-8

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, Francois E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F

Ann Oncol. 2012 Apr;23(4):919-27

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T, Uhl W, Van Tienhoven G, Bachet JB, Marechal R, Hendlisz A, Bali M, Demetter P, Ulrich F, Aust D, Luttges J, Peeters M, Mauer M, Roth A, Neoptolemos JP, Lutz M

Ann Oncol. 2012 Mar;23(3):570-6

[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].

Conroy T, Mitry E

Bull Cancer. 2011 Dec;98(12):1439-46

Metastatic pancreatic cancer: old drugs, new paradigms.

Conroy T, Gavoille C, Adenis A

Curr Opin Oncol. 2011 Jul;23(4):390-5.

Development of computerized adaptive testing (CAT) for the EORTC QLQ-C30 physical functioning dimension.

Petersen MA, Groenvold M, Aaronson NK, Chie WC, Conroy T, Costantini A, Fayers P, Helbostad J, Holzner B, Kaasa S, Singer S, Velikova G, Young T

Qual Life Res. 2011 May;20(4):479-90

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M

N Engl J Med. 2011 May 12;364(19):1817-25.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P

J Clin Oncol. 2011 May 1;29(13):1715-21

Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: the FATSEIN study.

Rotonda C, Guillemin F, Bonnetain F, Conroy T

Contemp Clin Trials. 2011 Mar;32(2):244-9

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.

Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis A, Faroux R, Rebischung C, Bergougnoux L, Kockler L, Douillard JY

Int J Cancer. 2011 Feb 1;128(3):682-90.

Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patients.

Giesinger JM, Aa Petersen M, Groenvold M, Aaronson NK, Arraras JI, Conroy T, Gamper EM, Kemmler G, King MT, Oberguggenberger AS, Velikova G, Young T, Holzner B

Health Qual Life Outcomes. 2011 Mar 29;9:19.

Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer.

Uwer L, Rotonda C, Guillemin F, Miny J, Kaminsky MC, Mercier M, Tournier-Rangeard L, Leonard I, Montcuquet P, Rauch P, Conroy T

Health Qual Life Outcomes. 2011 Aug 22;9:70.

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer.

Conroy T, Yataghene Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B, Rio E, Le Prise E, Peiffert D, Adenis A

Br J Cancer. 2010 Oct 26;103(9):1349-55

Development of computerised adaptive testing (CAT) for the EORTC QLQ-C30 dimensions - general approach and initial results for physical functioning.

Petersen MA, Groenvold M, Aaronson NK, Chie WC, Conroy T, Costantini A, Fayers P, Helbostad J, Holzner B, Kaasa S, Singer S, Velikova G, Young T

Eur J Cancer. 2010 May;46(8):1352-8

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La Roche G, Bouche O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahe MA, Becouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T

J Clin Oncol. 2010 Apr 1;28(10):1638-44

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial.

Methy N, Bedenne L, Conroy T, Bouche O, Chapet O, Ducreux M, Gerard JP, Bonnetain F

Ann Oncol. 2010 Mar;21(3):518-24

Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.

Perrocheau G, Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, Conroy T, Dominguez S, Faroux R, Florentin V, Douillard JY

Oncology. 2010;79(3-4):174-80

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.

Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Lledo G, Adenis A, Faroux R, Rebischung C, Kockler L, Douillard JY

Br J Cancer. 2010 Jan 5;102(1):59-67

Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer.

Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, Johnson CD, Pilkington SA, Arraras J, Ben-Josef E, Pullyblank AM, Fayers P, Blazeby JM

Eur J Cancer. 2009 Nov;45(17):3017-26

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F, Becouarn Y, Bouche O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A

Ann Oncol. 2009 Apr;20(4):674-80

[Clinical case: should esophageal cancers still be operated on?]

Conroy T

Gastroenterol Clin Biol. 2009 Apr;33(4):285-8

Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases.

Blazeby JM, Fayers P, Conroy T, Sezer O, Ramage J, Rees M

Br J Surg. 2009 Mar;96(3):291-8.

Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancer.

Adenis A, Conroy T

J Clin Oncol. 2009 Jan 20;27(3):467-8; author reply 468-9

Cetuximab with concurrent chemoradiation for esophagogastric cancer: in regard to Safran et al. (Int J Radiat Oncol Biol Phys 2008;70:391-395).

Adenis A, Mariette C, Mirabel X, Seitz JF, Conroy T

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):958-9.

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer.

Conroy T, Viret F, Francois E, Seitz JF, Boige V, Ducreux M, Ychou M, Metges JP, Giovannini M, Yataghene Y, Peiffert D

Br J Cancer. 2008 Nov 4;99(9):1395-401

Systematic review: Value of perioperative chemotherapy in the management of resectable rectal adenocarcinoma (brief report)

Becouarn Y, Guillo S, Antru P, Assenal E, Bossel JF, Conroy T, Francois E, Taieb J, Toubocl E

Bull Cancer. 2008 Jul-Aug;95(7):717-34.

Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C.

Rotonda C, Conroy T, Mercier M, Bonnetain F, Uwer L, Miny J, Montcuquet P, Leonard I, Adenis A, Breysacher G, Guillemin F

Qual Life Res. 2008 Apr;17(3):437-45

Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Federation Francophone de Cancerologie Digestive.

Burtin P, Bouche O, Giovannini M, Pelletier M, Conroy T, Ruget O, Arsene D, Milan C, Bedenne L

Gastroenterol Clin Biol. 2008 Mar;32(3):213-20

Systematic review: value of perioperative chemotherapy in the management of resectable rectal adenocarcinoma (brief report)

Becouarn Y, Guillo S, Artru P, Assenat E, Bosset JF, Conroy T, Francois E, Taieb J, Touboul E

Oncologie. 2008 Mar;10(3):226-32

Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer.

Byrne C, Griffin A, Blazeby J, Conroy T, Efficace F

Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S95-104

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach.

Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM

Eur J Cancer. 2007 Sep;43(14):2066-73

Assessing quality of life in patients with colorectal cancer: an update of the EORTC quality of life questionnaire.

Gujral S, Conroy T, Fleissner C, Sezer O, King PM, Avery KN, Sylvester P, Koller M, Sprangers MA, Blazeby JM

Eur J Cancer. 2007 Jul;43(10):1564-73

Health-related quality-of-life assessment in gastrointestinal cancer: are results relevant for clinical practice?

Conroy T, Uwer L, Deblock M

Curr Opin Oncol. 2007 Jul;19(4):401-6.

[Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]

Tournier-Rangeard L, Peiffert D, Lafond C, Mege A, Metayer Y, Marchesi V, Buchheit I, Uwer L, Conroy T, Kaminsky MC

Cancer Radiother. 2007 Jun;11(4):169-77

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C

J. Clin. Oncol.. 2007 Apr;25(10):1160-8

Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.

Hebbar M, Di Fiore F, Conroy T, Giraud C, Gasnault L, Fournier C, Pereira R, Bouche O, Fournier P, Deligny N, Joly JP, Maes P, Rad E, Michel P, Adenis A

Oncology. 2007;73(3-4):185-91

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L

J Clin Oncol. 2006 Oct 1;24(28):4620-5.

Metastatic colorectal cancer.

Bouche O, Conroy T, Michel P, Penna C, Tournigand C

Gastroenterol Clin Biol. 2006 Sep;30:S30-42.

Metastatic colorectal cancer.

Bouche O, Conroy T, Michel P, Penna C, Tournigand C

Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S30-2S42.

A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable

Bonnetain F, Bouché O, Michel P, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Paillot B, Arveux P, Milan C, Bedenne L

Ann. Oncol.. 2006 May;17(5):827-34

[Multisite validation study of questionnaire assessing out-patient satisfaction with care questionnaire in ambulatory chemotherapy or radiotherapy treatment].

Poinsot R, Altmeyer A, Conroy T, Savignoni A, Asselain B, Leonard I, Marx E, Cosquer M, Sevellec M, Gledhill J, Rodary C, Mercier M, Dickes P, Fabbro M, Antoine P, Guerif S, Schraub S, Dolbeault S, Bredart A

Bull Cancer. 2006 Mar 1;93(3):315-27.

[Recommendations for clinical practice: management with first-line palliative chemotherapy for patients with metastatic colorectal cancer].

Conroy T, Adeni A, Bouché O, Merrouche Y, Mitry E, Gory-Delabaere G, ,,,,,,,,,

Bull Cancer. 2006 Feb;93(2):197-200

Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?

Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schoffski P, Schmoll H, Van Cutsem E, Kohne CH

Eur J Cancer. 2006 Jan;42(1):42-9

Quality of life in patients with oesophageal and gastric cancer: an overview.

Conroy T, Marchal F, Blazeby JM

Oncology. 2006;70(6):391-402

Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.

Francois E, Ychou M, Ducreux M, Bertheault-Cvitkovic F, Giovannini M, Conroy T, Lemanski C, Thomas O, Magnin V

Eur J Cancer. 2005 Dec;41(18):2861-7

Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.

Lejeune C, Bismuth MJ, Conroy T, Zanni C, Bey P, Bedenne L, Faivre J, Arveux P, Guillemin F

J Nucl Med. 2005 Dec;46(12):2020-8.

Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.

Bonnetain F, Bouche O, Conroy T, Arveux P, Raoul JL, Giovannini M, Etienne PL, Mitry E, Seitz JF, Rougier P, Girault C, Bedenne L

Gastroenterol Clin Biol. 2005 Nov;29(11):1113-24.

An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32).

Bredart A, Bottomley A, Blazeby JM, Conroy T, Coens C, D'Haese S, Chie WC, Hammerlid E, Arraras JI, Efficace F, Rodary C, Schraub S, Costantini M, Costantini A, Joly F, Sezer O, Razavi D, Mehlitz M, Bielska-Lasota M, Aaronson NK

Eur J Cancer. 2005 Sep;41(14):2120-31.

Cancer in patient satisfaction assessment using the EORTC QLQ-SAT32: comparison between self-assessment and interview response.

Bredart A, Mignot V, Rousseau A, Dolbeault S, Beauloye N, Adam V, Elie C, Leonard I, Asselain B, Conroy T

Rev Epidemiol Sante Publique. 2005 Sep;53 Suppl. 1:31-8.

[Cancer patient's satisfaction assessment using the EORTC QLQ-SAT32: comparison between self-assessment and interview response]

Bredart A, Mignot V, Rousseau A, Dolbeault S, Beauloye N, Adam V, Elie C, Leonard I, Asselain B, Conroy T

Rev Epidemiol Sante Publique. 2005 Sep;53 Spec No 1:1S31-8.

Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.

Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, Guimares dos Santos J, Bleiberg H, Mackiewickz R, Conroy T, Bouché O, Morin T, Baila L, van Cutsem E, Bedenne L

Lancet Oncol.. 2005 Jul;6(7):459-68

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

Twelves CJ, Butts CA, Cassidy J, Conroy T, Braud F, Diaz-Rubio E, Tabernero JM, Schoffski P, Figer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ

Clin Colorectal Cancer. 2005 Jul;5(2):101-7.

[Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)].

Ychou M, Gory-Delabaere G, Blanc P, Bosquet L, Duffour J, Giovannini M, Guillemin F, Lemanski C, Marchal F, Masson B, Merrouche Y, Monges G, Adenis A, Bosset JF, Bouche O, Conroy T, Pezet D, Triboulet JP

Bull Cancer. 2005 Apr;92(4):381-409.

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, Deplanque G

J Clin Oncol. 2005 Feb 20;23(6):1228-36.

French version of FACT-G: validation and comparison with other cancer-specific instruments.

Conroy T, Mercier M, Bonneterre J, Luporsi E, Lefebvre JL, Lapeyre M, Puyraveau M, Schraub S

Eur J Cancer. 2004 Oct;40(15):2243-52.

[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)].

Conroy T, Gory-Delabaere G, Adenis A, Bosquet L, Bouché O, Louvet C, Mitry E, Bécouarn Y, Bosset JF, Ducreux M, Etienne PL, Merrouche Y, Monges G, Rougier P, ,,,,,,,

Bull Cancer. 2004 Oct;91(10):759-68

[Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy].

Ychou M, Gory-Delabaere G, Blanc P, Bosquet L, Duffour J, Giovannini M, Guillemin F, Lemanski C, Marchal F, Masson B, Merrouche Y, Monges G, Adenis A, Bosset JF, Bouché O, Conroy T, Pezet D, Triboulet JP, ,,

Cancer Radiother. 2004 Oct;8(5):322-35